Class-sparing regimens for initial treatment of HIV-1 infection.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The use of either efavirenz or lopinavir-ritonavir plus two nucleoside reverse-transcriptase inhibitors (NRTIs) is recommended for initial therapy for patients with human immunodeficiency virus type 1 (HIV-1) infection, but which of the two regimens has greater efficacy is not known. The alternative regimen of lopinavir-ritonavir plus efavirenz may prevent toxic effects associated with NRTIs.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): N Engl J Med

Title: The New England journal of medicine

Publisher: Massachusetts Medical Society

ISSN (Electronic): 1533-4406

ISSN (Print): 0028-4793

Publication date (Electronic): May 15 2008

Volume: 358

Issue: 20

Affiliations

[1 ] University of Pittsburgh, Pittsburgh, USA. riddler@dom.pitt.edu

Article

Publisher Item ID: 358/20/2095 Mid ID: NIHMS541544

DOI: 10.1056/NEJMoa074609

PMC ID: 3885902

PubMed ID: 18480202

SO-VID: f6d6fa2c-2b50-488c-be4e-b19651756a1b

History

Data availability:

Comments

Comment on this article

scite_

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.